alpidem
Small moleculeexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- Translocator proteinPARTIAL AGONIST
TSPO partial agonist
The anxiolytic and anticonvulsant properties of alpidem appear to be elicited both with a direct mechanism through the interaction with central benzodiazepine receptor (CBR) and with an indirect mechanism by the interaction with peripheral benzodiazepine receptor (PBR) as well as the stimulation of pregnenolone formation.
Alpidem binds with nanomolar affinity both peripheral benzodiazepine receptor (PBR) (Ki =0.5-7 nM) and central benzodiazepine receptor CBR (Ki =1-28 nM).
Chemistry & pharmacology
Loading structure…
SMILES
CCCN(CCC)C(=O)Cc1c(-c2ccc(Cl)cc2)nc2ccc(Cl)cn12- Mol. weight
- 404.34 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL54349 ↗
Also known as
- alpidem
- alpidem
- alpidem
- alpidem
- alpidem
- alpidem
- alpidem
- ananxyl
- s-800342
- sl 80-0342
- sl 80.0342-00
- sl 80.0342-00